Grimm, MO;Machiels, JP;Wülfing, C;Richel, D;Treiber, U;de Groot, M;Beuzeboc, P;Farrell, J;Colman, J;El-Hariry, I
A single arm, multicentre, open-label phase II study of orally administered lapatinib (GW572016) as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma
Ann Oncol
2005
16 Suppl.
41-41

Wülfing, C;Machiels, JP;Richel, D;Grimm, MO;Treiber, U;de Groot, M;Beuzeboc, P;Farrell, J;Stone, NL;Leopold, L;El-Hariry, I
A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract
J Clin Oncol
2005
23
16
401S-401S

Elhilali, M;Vallancien, G;van Moorselaar, J;Harving, N;Hartung, R;Emberton, M;Alcaraz, A;Matzkin, H
Beneficial effects of alfuzosin 10mg OD on LUTS, quality of life and sexual function: A 2-year experience in BPH patients in real life practice
J Urol
2005
173 Suppl.
4
463-463

Treiber, U;Bossner, P;Kubler, H;van Randenborgh, H;Paul, R;Piert, M;Schwaiger, M;Hartung, R
Diagnostic efficiency of 11C-choline PET in patients with bladder cancer scheduled for radical cystectomy
J Urol
2005
173 Suppl.
4
373-373

Emberton, M;Elhilali, M;Hartung, R;Alcaraz, A;Harving, N;Matzkin, H;van Moorselaar, J
Response or not to alfuzosin treatment is predictive of AUR and BPH surgery
J Urol
2005
173 Suppl.
4
463-463

van Moorselaar, J;Harving, N;Matkin, H;Emberton, M;Hartung, R;Alcaraz, A;Elhilali, M;Vallancien, G
Improvement of sexual function with alfuzosin 10mg once daily is related to baseline LUTs and bother severity
J Urol
2005
173 Suppl.
4
461-461

Alschibaja, M;Mueller, C;Massmann, J;Funk, A;van Randenborgh, H;Hartung, R;Paul, R
Definition of risk groups for PSA failure after radical prostatectomy - Tumour volume or multivariate analysis?
J Urol
2005
173 Suppl.
4
281-281

Retz, MM;Sidhu, SS;Blaveri, E;Kerr, SC;Dolganov, GM;Lehmann, J;Carroll, P;Simko, J;Waldman, FM;Basbaum, C
CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells.
Int J Cancer
2005
114
2
182-9

Retz, M;Sidhu, SS;Lehmann, J;Tamamura, H;Fujii, N;Basbaum, C
New HIV-drug inhibits in vitro bladder cancer migration and invasion.
Eur Urol
2005
48
6
1025-30

Lehmann, J;Retz, M;Wiemers, C;Beck, J;Thüroff, J;Weining, C;Albers, P;Frohneberg, D;Becker, T;Funke, PJ;Walz, P;Langbein, S;Reiher, F;Schiller, M;Miller, K;Roth, S;Kalble, T;Sternberg, D;Wellek, S;Stöckle, M
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
J Clin Oncol
2005
23
22
4963-74